Medicare Covers Ozempic for Diabetes — Not Weight Loss — but a $50/Month Pilot Program Launches July 2026

🔑 10 Key Takeaways You Need Right Now

Medicare Part D covers Ozempic only when prescribed for type 2 diabetes — not for weight loss. This is federal law under the Medicare Modernization Act of 2003, and no individual plan can override it.

Wegovy is now covered by some Part D plans for cardiovascular risk reduction — but only in adults with established cardiovascular disease who are also overweight or obese. Weight loss alone is not a qualifying indication.

There is no legitimate way to get Ozempic for $25 a month through Medicare — the lowest confirmed future copay is $50/month under the CMS GLP-1 payment demonstration launching July 2026, and even that requires meeting specific eligibility criteria.

The BALANCE Model pilot begins July 2026 for Medicare beneficiaries — eligible enrollees with obesity and qualifying conditions (prediabetes, cardiovascular disease, uncontrolled hypertension, kidney disease, or heart failure) will pay $50/month. The government pays $245/month per beneficiary.

Ozempic’s list price is approximately $998 per month without insurance — but Novo Nordisk’s self-pay program offers the injection at $199/month for new patients (introductory price as of early 2026).

Only 13 state Medicaid programs cover GLP-1 medications for obesity as of January 2026 — and the number is shrinking. California eliminated Medi-Cal coverage for weight loss GLP-1s effective January 1, 2026, while North Carolina reinstated coverage in December 2025 after briefly dropping it.

Zepbound (tirzepatide) is covered by some Part D plans for obstructive sleep apnea — not for weight loss. This is a separate FDA-approved indication that many beneficiaries with obesity may qualify for.

Semaglutide products (Ozempic, Wegovy, Rybelsus) have been selected for Medicare price negotiation — negotiated prices take effect in 2027, which could dramatically lower costs across the board.

The Part D out-of-pocket cap of $2,100 in 2026 protects beneficiaries on covered GLP-1s — once you hit this annual ceiling, Medicare pays 100% of your remaining covered drug costs for the year.

Medicare Part B covers intensive behavioral therapy for obesity at no cost — this benefit includes up to 22 face-to-face counseling visits in the first year with a primary care provider, and most beneficiaries don’t even know it exists.

💊 Yes, Medicare Covers Ozempic — but Only If Your Doctor Writes the Right Diagnosis Code

This is the single most important distinction that separates beneficiaries who get coverage from those who get a denial letter. Medicare Part D plans can and do cover Ozempic (semaglutide), but the prescription must be written for an FDA-approved indication other than weight loss. The moment “obesity” or “weight management” appears as the primary diagnosis, the claim is automatically rejected.

Here’s exactly which GLP-1 medications Medicare Part D can cover in 2026, and for which diagnoses:

💊 Medication	Active Ingredient	✅ Covered Diagnosis	❌ Not Covered For
🟢 Ozempic (injection)	Semaglutide	Type 2 diabetes (blood sugar control)	Weight loss, obesity, prediabetes
🟢 Rybelsus (oral tablet)	Semaglutide	Type 2 diabetes	Weight loss, obesity
🟢 Mounjaro (injection)	Tirzepatide	Type 2 diabetes	Weight loss, obesity
🟡 Wegovy (injection/pill)	Semaglutide	Cardiovascular risk reduction in adults with established CVD who are overweight/obese	Weight loss alone, obesity without CVD
🟡 Zepbound (injection)	Tirzepatide	Moderate-to-severe obstructive sleep apnea in adults with obesity	Weight loss alone, obesity without OSA
🔴 Saxenda (injection)	Liraglutide	No currently covered Medicare indication	Weight loss (FDA-approved for weight management but excluded by Medicare)
🟢 Victoza (injection)	Liraglutide	Type 2 diabetes	Weight loss, obesity
🟢 Trulicity (injection)	Dulaglutide	Type 2 diabetes	Weight loss, obesity

The critical insider detail: coverage is indication-specific, not drug-specific. The exact same molecule — semaglutide — is sold as Ozempic for diabetes and Wegovy for weight loss/cardiovascular risk. Medicare’s computer systems check the diagnosis code attached to the prescription, not just the drug name. If your doctor prescribes Ozempic with the ICD-10 code E11 (type 2 diabetes mellitus), your Part D plan processes it as a diabetes medication. If the code is E66 (obesity), it’s rejected.

This doesn’t mean doctors should misrepresent diagnoses. But many patients with obesity genuinely also have type 2 diabetes, prediabetes, cardiovascular disease, or sleep apnea — and an experienced physician will document all relevant conditions to ensure the prescription reflects the full clinical picture.

💰 The $25 Ozempic Myth vs. What You’ll Actually Pay in 2026

Let’s address the viral claim directly: there is no verified program offering Ozempic at $25 per month through Medicare or any manufacturer program as of February 2026. Various social media posts and misleading advertisements have promoted this number, but it doesn’t correspond to any real program. Here’s what actually exists:

💰 Payment Path	Monthly Cost	Who Qualifies	Available When
🏥 Medicare Part D (Ozempic for diabetes)	Varies by plan: $30–$150+ after deductible, then $0 after $2,100 annual cap	Beneficiaries with type 2 diabetes whose plan formulary includes Ozempic	Now
🆕 CMS GLP-1 Payment Demonstration	$50/month (government pays $245)	Part D beneficiaries meeting BMI and comorbidity criteria	July 2026
💊 Novo Nordisk Self-Pay (Ozempic injection)	$199/month introductory (2 fills), then $299/month	Cash-paying patients, not valid with insurance	Now through March 31, 2026 (introductory offer)
💊 Novo Nordisk Self-Pay (Wegovy pill)	$149/month introductory, then $349/month	Cash-paying patients new to treatment	Now (pill available in pharmacies since January 2026)
🏷️ TrumpRx.gov portal	$199/month Ozempic injection, $149/month Wegovy pill	Self-pay consumers with a prescription, not for use with Medicare/Medicaid	Now
🆘 Novo Nordisk Patient Assistance	$0 (free)	Uninsured patients meeting income criteria	Now
🏦 NovoCare Pharmacy (home delivery)	$499/month all doses of Wegovy	Cash-paying patients	Now

For Medicare beneficiaries currently covered for Ozempic under a diabetes diagnosis, the actual out-of-pocket cost depends on your plan’s formulary tier, whether prior authorization is required, and where you fall in the Part D benefit phases. In 2026, the Part D deductible can be up to $615, after which you typically pay 25% coinsurance until you hit the $2,100 annual out-of-pocket cap. Once you reach that cap, all covered drugs cost $0 for the rest of the year.

If you qualify for Extra Help (the Low-Income Subsidy), your copays drop to $5.10 for generic drugs and $12.65 for brand-name drugs — making covered GLP-1 medications remarkably affordable for low-income beneficiaries.

🏥 The 5 Diagnoses That Unlock GLP-1 Coverage Under Medicare Right Now

Understanding which medical conditions trigger Medicare coverage for GLP-1 medications is the difference between paying $0 (after your out-of-pocket cap) and paying $998 per month out of pocket. Here are the five clinical pathways that currently work:

Pathway 1: Type 2 diabetes mellitus (ICD-10: E11.x) This is the most straightforward route. If you have a confirmed type 2 diabetes diagnosis with an A1C above target, your doctor can prescribe Ozempic, Mounjaro, Rybelsus, Victoza, or Trulicity, and most Part D plans will cover it. Prior authorization typically requires documentation of failed first-line therapy (metformin) or a contraindication.

Pathway 2: Cardiovascular risk reduction with overweight/obesity (Wegovy only) Since the FDA approved Wegovy’s cardiovascular indication in March 2024, Part D plans may cover it for adults with established cardiovascular disease (prior heart attack, stroke, or peripheral artery disease) who also have a BMI of 27 or greater. Your cardiologist and prescribing physician must document the cardiovascular history and BMI.

Pathway 3: Obstructive sleep apnea with obesity (Zepbound only) The FDA approved Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity in December 2024. If you have a documented sleep study confirming OSA and a BMI of 30 or greater, your Part D plan may cover Zepbound specifically for this indication.

Pathway 4: Chronic kidney disease with type 2 diabetes Semaglutide has shown kidney-protective effects in clinical trials. Some Part D plans cover Ozempic for patients with type 2 diabetes and chronic kidney disease, as the cardiovascular and renal benefits provide additional clinical justification beyond blood sugar control alone.

Pathway 5: BALANCE Model pilot — obesity with qualifying comorbidities (starting July 2026) The upcoming CMS demonstration will create the first direct pathway for Medicare beneficiaries to access GLP-1s for obesity treatment. Eligibility is expected to follow a phased approach. Phase 1 targets beneficiaries with a BMI over 27 plus prediabetes, or those with diagnosed cardiovascular disease. Phase 2 expands to BMI over 30 with uncontrolled hypertension, kidney disease, or heart failure.

🔄 The July 2026 Game-Changer: How the Balance Model and GLP-1 Demonstration Actually Work

The CMS announcement on December 23, 2025 set up a two-stage system for expanding GLP-1 access through Medicare and Medicaid:

🔄 Program	Launch Date	Who Participates	Beneficiary Cost	How It Works
🌉 GLP-1 Payment Demonstration (bridge program)	July 2026	Medicare Part D beneficiaries meeting criteria; operates outside Part D benefit structure	$50/month after deductibles	CMS administers directly; Part D plans carry no risk; government pays $245/month
🏗️ BALANCE Model (permanent structure)	January 2027 for Medicare Part D; May 2026 for Medicaid	Part D plan sponsors (PDPs and MA-PDs) who voluntarily opt in	To be determined per plan	CMS negotiates pricing with manufacturers; plans integrate into formularies
💊 GENEROUS Model (Medicaid)	January 2026 (rolling state enrollment through August 2026)	State Medicaid agencies that opt in	Varies by state	International reference pricing through CMS-manufacturer negotiations

Here’s what most articles won’t tell you: participation in all three programs is voluntary at every level. Drug manufacturers must agree to CMS pricing terms. Part D plan sponsors must choose to participate. State Medicaid agencies must opt in individually. This means there is no guarantee that your specific Part D plan or your state’s Medicaid program will offer these lower prices. Not all beneficiaries will automatically gain access.

The demonstration also operates outside the normal Part D benefit structure, meaning the $50 monthly copay for the bridge program doesn’t count toward your Part D deductible or annual out-of-pocket cap the way regular covered prescriptions do. CMS has stated it will release additional design and implementation details in early 2026.

🗺️ Medicaid GLP-1 Coverage for Obesity: Only 13 States as of January 2026

While Medicare’s rules are uniform across all states, Medicaid coverage for GLP-1 weight loss medications varies dramatically. All state Medicaid programs must cover GLP-1s prescribed for type 2 diabetes (required under federal drug rebate law), and since 2024, coverage is also required for Wegovy’s cardiovascular indication and Zepbound’s sleep apnea indication. But coverage for obesity treatment alone remains optional — and most states have chosen not to cover it.

🗺️ State Coverage Status (January 2026)	States
🟢 Cover GLP-1s for obesity treatment under Medicaid FFS	Approximately 13 states, including: Iowa, Minnesota, New Mexico, North Carolina (reinstated December 2025), Pennsylvania, West Virginia, Wyoming, and others
🟡 Partial coverage (some GLP-1s, with restrictions)	Arizona, Colorado, Texas, Washington, and approximately 18 other states covering Wegovy and/or Saxenda with prior authorization
🔴 No Medicaid coverage for obesity-indicated GLP-1s	New York, Illinois, Ohio, Florida, New Jersey, District of Columbia, and approximately 8 other states — beneficiaries can only access GLP-1s with a diabetes diagnosis
⚠️ Recently eliminated obesity coverage	California (ended January 1, 2026), Massachusetts (ended January 1, 2025 for adults), Michigan (restricting), Nebraska (ended)

The trend is concerning: states are actually pulling back coverage rather than expanding it. California’s elimination of Medi-Cal GLP-1 coverage for weight loss affects the single largest state Medicaid population in the country. The state cited budget constraints — these medications cost approximately $1,350 per month per patient at list price, and California’s Medicaid spending on GLP-1s alone exceeded $1.4 billion in the 12 months ending October 2024.

The GENEROUS and BALANCE models could reverse this trend if enough states opt in and manufacturers agree to pricing terms that make coverage sustainable. But as of February 2026, no state has publicly confirmed participation timelines.

⚕️ Medicare Part B Already Covers Free Obesity Counseling — and Almost Nobody Uses It

While the Part D weight-loss drug exclusion gets all the attention, Medicare Part B has quietly covered intensive behavioral therapy (IBT) for obesity since 2011, at zero cost to beneficiaries. This benefit provides up to 22 face-to-face counseling sessions in the first year, followed by monthly visits if you achieve at least 6.6 pounds of weight loss in the first 6 months.

⚕️ Medicare-Covered Weight Management Services (2026)	Details
🩺 Intensive Behavioral Therapy for Obesity (Part B)	Up to 22 visits in year one with a primary care provider; $0 cost with qualifying BMI of 30+
🏋️ Diabetes Prevention Program (Part B)	Structured lifestyle intervention for prediabetes; group-based classes over 24 months
🍎 Medical Nutrition Therapy (Part B)	Covered for diabetes and kidney disease; provided by registered dietitians
💪 SilverSneakers / fitness benefits (some MA plans)	95% of 2026 Medicare Advantage plans include fitness program benefits
🧠 Behavioral health counseling (Part B)	Mental health support for emotional eating patterns; covered under Part B behavioral health benefit

The IBT benefit is dramatically underutilized. Fewer than 1% of eligible Medicare beneficiaries have ever used it, despite costing nothing. The counseling must be provided by a primary care physician, physician assistant, or nurse practitioner in a primary care setting — which is a limitation, since many weight management specialists operate outside primary care. Some Medicare Advantage plans have expanded this benefit to include registered dietitians and telehealth delivery.

💊 The Oral Wegovy Pill Changes Everything Starting 2026

One of the most significant developments in the GLP-1 landscape arrived in December 2025, when the FDA approved the first oral formulation of Wegovy (semaglutide) for chronic weight management. The once-daily pill began appearing in pharmacies in January 2026, and it fundamentally changes the accessibility equation for several reasons.

First, many patients who resist injectable medications will now have a pill option. Second, oral semaglutide may be easier to integrate into the BALANCE Model and Part D formularies. Third, Novo Nordisk has priced the introductory self-pay cost at $149/month for the lowest doses — significantly less than the $998 list price of injectable Ozempic or the $1,350 list price of injectable Wegovy.

For Medicare beneficiaries, the oral Wegovy pill follows the same coverage rules as the injection: it’s covered for cardiovascular risk reduction in adults with established CVD and overweight/obesity, but not for weight loss alone. However, the lower price point may accelerate its inclusion in Part D plan formularies and reduce cost-sharing for beneficiaries whose plans do cover it.

💰 Ozempic, Wegovy, and Rybelsus Are Heading to Medicare Price Negotiation in 2027

In what could be the most consequential long-term development, all three of Novo Nordisk’s semaglutide products — Ozempic, Wegovy, and Rybelsus — have been selected for the second round of Medicare drug price negotiation under the Inflation Reduction Act. Negotiated prices will take effect in 2027.

The Congressional Budget Office and independent analysts expect semaglutide prices to drop significantly once negotiation concludes. The first round of negotiations (covering 10 drugs with 2026 effective dates) produced average price reductions of 38–79% off list prices. If similar reductions apply to semaglutide, the per-month cost to Medicare could fall from the current $998 list price to potentially $200–$600, depending on the negotiated outcome.

This price reduction would simultaneously reduce beneficiary cost-sharing under Part D (since copays and coinsurance are calculated based on the drug’s price), reduce the government’s cost under the BALANCE Model, and make it more financially sustainable for states to cover semaglutide under Medicaid.

❓ Frequently Asked Questions

Does Medicare cover Ozempic for weight loss? No. Federal law under the Medicare Modernization Act of 2003 explicitly excludes drugs prescribed for weight loss from Part D coverage. Ozempic is covered only when prescribed for its FDA-approved indication of type 2 diabetes. However, starting July 2026, a CMS payment demonstration will allow eligible beneficiaries with obesity and qualifying comorbidities to access GLP-1 medications at a $50 monthly copay.

How do I get Ozempic for $25 a month? There is no verified program offering Ozempic at $25 per month as of February 2026. The lowest confirmed future copay is $50/month under the CMS GLP-1 payment demonstration beginning July 2026. For current self-pay options, Novo Nordisk offers an introductory price of $199/month for the first two fills. If you have Part D coverage for a diabetes indication and qualify for Extra Help (Low-Income Subsidy), your copay could be as low as $5.10–$12.65.

What diagnosis will cover Ozempic under Medicare? The primary covered diagnosis is type 2 diabetes mellitus (ICD-10 code E11.x). Your doctor must document that Ozempic is being prescribed for blood sugar management, typically after first-line therapy (metformin) has been tried or is contraindicated. Some plans also accept documentation of related cardiovascular or renal complications as supporting clinical justification.

Does Medicare cover Wegovy for heart disease? Yes, some Part D plans now cover Wegovy when prescribed specifically to reduce the risk of cardiovascular death, heart attack, or stroke in adults with established cardiovascular disease who are also overweight or obese (BMI 27+). This coverage is based on the FDA’s March 2024 approval of Wegovy’s cardiovascular risk reduction indication. Coverage requires prior authorization and clinical documentation of both the cardiovascular history and BMI.

How much does Ozempic cost with Medicare in 2026? If your Part D plan covers Ozempic for diabetes, you’ll first pay your plan’s deductible (up to $615 in 2026), then typically 25% coinsurance until you reach the $2,100 annual out-of-pocket cap. Once you hit that cap, all covered drugs cost $0 for the rest of the year. For a drug with a monthly cost near $998, you could reach the $2,100 cap within 3–4 months, after which Ozempic would be free for the remainder of the year.

Does Medicaid cover Wegovy? It depends on your state. As of January 2026, only about 13 state Medicaid programs cover GLP-1 medications for obesity under fee-for-service. All states must cover Wegovy when prescribed for cardiovascular risk reduction or when prescribed for FDA-approved diabetes indications. California eliminated Medi-Cal coverage of GLP-1s for weight loss effective January 1, 2026. Contact your state Medicaid office to verify current coverage.

When will Medicare fully cover weight loss drugs? There is no confirmed date for removing the statutory exclusion on weight-loss drugs from Medicare. The Treat and Reduce Obesity Act, a bipartisan bill that would eliminate this exclusion, has been introduced in multiple congressional sessions but has not passed. The CMS BALANCE Model (January 2027 for full Part D integration) and the bridge demonstration (July 2026) represent the closest current path to broader access, though both are voluntary pilot programs with eligibility restrictions.

Is there a generic version of Ozempic available? No. Semaglutide is still under patent protection, and no generic or biosimilar version is available in the United States as of February 2026. The selection of semaglutide products for Medicare price negotiation in 2027 may reduce costs significantly, but a true generic alternative is likely years away.

Can my doctor prescribe Ozempic “off-label” for weight loss and have Medicare cover it? While doctors can legally prescribe medications off-label, Medicare Part D plans generally will not cover drugs prescribed outside their FDA-approved indications when those uses fall into excluded categories. Weight loss is a specifically excluded category under federal law, so even an off-label Ozempic prescription for obesity would be denied by Part D.

What should I do if my Part D plan denies coverage for a GLP-1 medication? First, confirm whether the denial is due to the weight-loss exclusion (which cannot be overridden) or a formulary/prior authorization issue (which can be appealed). If your doctor prescribed the medication for a covered indication like diabetes, ask your physician to submit a coverage determination request with full clinical documentation, including lab results, treatment history, and the specific diagnosis code. If denied, you have the right to appeal through five levels, from the plan level up to federal court. If the denial stands because weight loss is the primary indication, explore the manufacturer’s patient assistance programs, the July 2026 CMS demonstration, and whether an alternative covered GLP-1 might be appropriate for another qualifying condition you may have.